<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dbv Technologies Sa — News on 6ix</title>
<link>https://6ix.com/company/dbv-technologies-sa-1</link>
<description>Latest news and press releases for Dbv Technologies Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 21:19:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dbv-technologies-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52fdbbeedb30cb6f6cd5d.webp</url>
<title>Dbv Technologies Sa</title>
<link>https://6ix.com/company/dbv-technologies-sa-1</link>
</image>
<item>
<title>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-filing-of-2025-annual-report-on-form-10-k-and-universal-registration-document-1</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-filing-of-2025-annual-report-on-form-10-k-and-universal-registration-document-1</guid>
<pubDate>Thu, 26 Mar 2026 21:19:00 GMT</pubDate>
<description>Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the Fr</description>
</item>
<item>
<title>DBV Technologies Reports Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-reports-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-reports-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Thu, 26 Mar 2026 21:06:00 GMT</pubDate>
<description>Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Bolstered executive leadership team in preparation for BLA submission and potential approvalReported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received o</description>
</item>
<item>
<title>DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</guid>
<pubDate>Tue, 24 Mar 2026 20:30:00 GMT</pubDate>
<description>Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The c</description>
</item>
<item>
<title>DBV Technologies to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-upcoming-march-investor-conferences-71</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-upcoming-march-investor-conferences-71</guid>
<pubDate>Wed, 04 Mar 2026 21:30:00 GMT</pubDate>
<description>Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in March: Citizens Life Sciences Conference – March 10, 2026Format: Fireside Chat Time: 1:40pm ET Leerink Partners Global Healthcare Conference – March 11, 2026Format: 1 on 1 Meetings Sign u</description>
</item>
<item>
<title>DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting-1</guid>
<pubDate>Sat, 28 Feb 2026 19:25:00 GMT</pubDate>
<description>Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group24% of childre</description>
</item>
<item>
<title>DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskinr-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskinr-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai-2026-annual-meeting</guid>
<pubDate>Tue, 10 Feb 2026 21:30:00 GMT</pubDate>
<description>Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from th</description>
</item>
<item>
<title>DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summit</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summit</guid>
<pubDate>Mon, 09 Feb 2026 21:30:00 GMT</pubDate>
<description>Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé’s presenta</description>
</item>
<item>
<title>DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-euro1667-million-in-gross-proceeds-following-the-full-exercise-of-the-absa-warrants-and-bs-warrants-issued-on-its-march-2025-financing</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-euro1667-million-in-gross-proceeds-following-the-full-exercise-of-the-absa-warrants-and-bs-warrants-issued-on-its-march-2025-financing</guid>
<pubDate>Fri, 16 Jan 2026 23:11:00 GMT</pubDate>
<description>Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Com</description>
</item>
<item>
<title>Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/half-year-report-on-the-dbv-technologies-liquidity-contract-with-oddo-bhf</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/half-year-report-on-the-dbv-technologies-liquidity-contract-with-oddo-bhf</guid>
<pubDate>Wed, 07 Jan 2026 21:00:00 GMT</pubDate>
<description>AMF Regulated InformationChâtillon, France, January 7, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2025: 74,580 DBV Techn</description>
</item>
<item>
<title>DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskinr-peanut-patch-in-peanut-allergic-children-aged-4-7-years</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskinr-peanut-patch-in-peanut-allergic-children-aged-4-7-years</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the plac</description>
</item>
<item>
<title>ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/alk-appoints-edward-jordan-as-new-evp-and-head-of-commercial-operations-north-america-1</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/alk-appoints-edward-jordan-as-new-evp-and-head-of-commercial-operations-north-america-1</guid>
<pubDate>Mon, 01 Dec 2025 14:35:00 GMT</pubDate>
<description>ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jo</description>
</item>
<item>
<title>DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-last-patient-visit-completed-in-vitesse-phase-3-clinical-trial-of-viaskinr-peanut-patch-in-peanut-allergic-children-aged-4-7-years</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-last-patient-visit-completed-in-vitesse-phase-3-clinical-trial-of-viaskinr-peanut-patch-in-peanut-allergic-children-aged-4-7-years</guid>
<pubDate>Wed, 12 Nov 2025 04:50:00 GMT</pubDate>
<description>Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VI</description>
</item>
<item>
<title>DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference</guid>
<pubDate>Tue, 04 Nov 2025 21:30:00 GMT</pubDate>
<description>Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts. A li</description>
</item>
<item>
<title>DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-appoints-industry-leader-kevin-trapp-as-chief-commercial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-appoints-industry-leader-kevin-trapp-as-chief-commercial-officer</guid>
<pubDate>Mon, 03 Nov 2025 21:30:00 GMT</pubDate>
<description>Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global</description>
</item>
<item>
<title>DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-appointment-of-philina-lee-phd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-appointment-of-philina-lee-phd-to-board-of-directors</guid>
<pubDate>Thu, 30 Oct 2025 20:30:00 GMT</pubDate>
<description>Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the rati</description>
</item>
<item>
<title>DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-upcoming-acaai-2025-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-to-participate-in-upcoming-acaai-2025-annual-scientific-meeting</guid>
<pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
<description>Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasti</description>
</item>
<item>
<title>DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-sale-of-approximately-dollar30-million-of-adss-through-its-at-the-market-atm-program-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-sale-of-approximately-dollar30-million-of-adss-through-its-at-the-market-atm-program-on-nasdaq</guid>
<pubDate>Wed, 29 Oct 2025 22:47:00 GMT</pubDate>
<description>Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”)</description>
</item>
<item>
<title>DBV Technologies Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-reports-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-reports-third-quarter-2025-financial-results</guid>
<pubDate>Tue, 28 Oct 2025 20:25:00 GMT</pubDate>
<description>Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the "Company"), reported financial results for the third quarter of 2025. The quarterly and nine months unaudited financial stat</description>
</item>
<item>
<title>DBV Technologies Announces Resignation of Board Member</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-resignation-of-board-member</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-announces-resignation-of-board-member</guid>
<pubDate>Thu, 18 Sep 2025 20:30:00 GMT</pubDate>
<description>Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Ros</description>
</item>
<item>
<title>DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq</title>
<link>https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-establishes-an-at-the-market-atm-program-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa-1/news/dbv-technologies-establishes-an-at-the-market-atm-program-on-nasdaq</guid>
<pubDate>Fri, 05 Sep 2025 20:30:00 GMT</pubDate>
<description>Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an at-the-market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, in</description>
</item>
</channel>
</rss>